Drug intelligence / Profile preview

doxorubicin + pembrolizumab

Development stage: Unknown
Lead developer: Merck
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous

Overview

Doxorubicin + pembrolizumab is a combination therapy consisting of doxorubicin, an anthracycline chemotherapy agent, and pembrolizumab, a PD-1 blocking antibody. Doxorubicin damages cancer cell DNA and blocks enzymes needed for cell division and DNA repair. Pembrolizumab works by releasing PD-1 pathway-mediated inhibition of the immune response, enhancing anti-tumor immune activity. This combination has shown promising activity in treating various sarcoma subtypes, particularly undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated liposarcoma, with manageable toxicity profiles.

Targets

TOP2A (DNA topoisomerase II)DNAPDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on doxorubicin + pembrolizumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on doxorubicin + pembrolizumab.

Explore the full profile